Chemical structure of "compound 1" GSK αvβ6 integrin inhibitor (GSK 3008348)

avb6 integrin inhibitor + lysosomal degrader

in vitro degradation, Ph. I completed, discont.

derived from prior integrin inhibitors

J. Pharmacol. Exp. Ther., Jan. 26, 2021

GlaxoSmithKline, Stevenage, UK

The GSK αvβ6 integrin inhibitor, “compound 1,” or GSK 3008348 is a previously reported IPF clinical candidate that is a picomolar binder to αvβ6 with slow dissociation kinetics. The…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.